Mark F. Brady

20.6k citations

111 papers · 12.0k indexed · 8 hit papers · h-index 42

Impact in

Reproductive Medicine top 0.01%
- Ovarian cancer diagnosis and treatment
- Endometriosis Research and Treatment
Obstetrics and Gynecology top 0.05%
- Endometrial and Cervical Cancer Treatments
- Uterine Myomas and Treatments

Papers in

Reproductive Medicine 78
- Ovarian cancer diagnosis and treatment 78
Obstetrics and Gynecology 29
- Endometrial and Cervical Cancer Treatments 27

Co-authors: William P. McGuire Howard D. Homesley Paul R. Kucera Daniel L. Clarke‐Pearson Robert A. Burger Katherine Y. Look William J. Hoskins Edward E. Partridge
Journals: Journal of Clinical Oncology (27 papers)Gynecologic Oncology (26 papers)Cancer (7 papers)Annals of Oncology (7 papers)International Journal of Gynecological Cancer (6 papers)
Partner nations: United States Japan United Kingdom

In The Last Decade

Mark F. Brady

109 papers receiving 11.7k citations

Hit Papers

8 papers align trajectories log scale

Bevacizumab and paclitaxel–carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial 2017 · 406 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2017 The Lancet Oncology
2016 New England Journal of Medicine
2015 JAMA Oncology
2011 New England Journal of Medicine
2009 Journal of Clinical Oncology
1996 New England Journal of Medicine
1994 American Journal of Obstetrics and Gynecology
1993 Cancer

Peers

Countries citing papers authored by Mark F. Brady

Since Specialization

Citations

This map shows the geographic impact of Mark F. Brady's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark F. Brady with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark F. Brady more than expected).

Fields of papers citing papers by Mark F. Brady

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark F. Brady. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark F. Brady. The network helps show where Mark F. Brady may publish in the future.

Co-authors

The 25 scholars most cited alongside Mark F. Brady, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Mark F. Brady Line = papers co-authored together Mark F. Brady links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	LBA45 Overall survival (OS) outcomes from NRG-GY004, a phase III study comparing single-agent olaparib or combination cediranib and olaparib to platinum (Plat) based chemotherapy in recurrent plat sensitive ovarian cancer (OvCa) Annals of Oncology ·J.F. Liu, Mark F. Brady, Ursula A. Matulonis, Austin Miller, Elise C. Kohn, Elizabeth M. Swisher, William P. Tew, Noelle Cloven, Carolyn Y. Muller, David Bender, Richard G. Moore, M. Menon, Steven Waggoner, Melissa A. Geller, Keiichi Fujiwara, Stacy D. D’Andre, Michael E. Carney, Angeles Alvarez Secord, Joan Walker, M.A. Bookman	2023	2
2	LBA34 Association of homologous recombination deficiency (HRD) with clinical outcomes in a phase III study of olaparib or cediranib and olaparib compared to platinum-based chemotherapy in recurrent platinum-sensitive ovarian cancer (PSOC): Biomarker analyses from NRG-GY004 Annals of Oncology ·Elizabeth M. Swisher, Austin Miller, Elise C. Kohn, Mark F. Brady, Marc R. Radke, Christopher C. Pennil, Nithisha Khasnavis, Joseph Buscema, William P. Tew, Carolyn Y. Muller, Emily K. Hill, Richard G. Moore, M. Menon, Steven Waggoner, Melissa A. Geller, Keiichi Fujiwara, Stacy D. D’Andre, J. Liu, Michael J. Birrer	2021	4
3	818P Veliparib with carboplatin and paclitaxel in frontline high-grade serous ovarian cancer (HGSOC): Efficacy and safety of paclitaxel weekly and every 3 weeks in the VELIA study Annals of Oncology ·Aikou Okamoto, Gini F. Fleming, Michael A. Bookman, Mark F. Brady, Elizabeth M. Swisher, Karina Dahl Steffensen, Noelle Cloven, Takayuki Enomoto, David M. O’Malley, Linda Van Le, Krishnansu S. Tewari, Joyce N. Barlin, William H. Bradley, Kathleen N. Moore, John K. Chan, Meijing Wu, H. Hashiba, Minh H. Dinh, Robert L. Coleman, Carol Aghajanian	2020	2
4	Legionnaires' Disease (Legionella Infection) Mark F. Brady, Vidya Sundareshan	2019	2
5	Tapeworm (Taenia Solium, Taenia Saginata, Diphyllobothrium, Cysticercosis, Neurocysticercosis) StatPearls ·Ellen Lesh, Mark F. Brady	2019	3
6	Gynecological Cancers Translational, Research Implementation, and Harmonization: Gynecologic Cancer InterGroup Consensus and Still Open Questions Cells ·Marina Bagnoli, Tingyan Shi, Charlie Gourley, P Speiser, Alexander Reuß, Hans W. Nijman, Carien L. Creutzberg, Suzy Scholl, Anastassia Negrouk, Mark F. Brady, Kosei Hasegawa, Katsutoshi Oda, Iain A. McNeish, Elise C. Kohn, Amit M. Oza, Helen Mackay, David Millan, Katherine Bennett, Clare L. Scott, Delia Mezzanzanica	2019	6
7	Measurements of adiposity as prognostic biomarkers for survival with anti-angiogenic treatment in epithelial ovarian cancer: An NRG Oncology/Gynecologic Oncology Group ancillary data analysis of GOG 218 Gynecologic Oncology ·Katrina Wade, Mark F. Brady, Theresa Thai, Y. Wang, Bin Zheng, Ritu Salani, Krishnansu S. Tewari, Heidi J. Gray, Jamie N. Bakkum‐Gamez, Robert A. Burger, Kathleen N. Moore, Michael A. Bookman	2019	11
8	A phase II study of paclitaxel for the treatment of ovarian stromal tumors: An NRG Oncology/ Gynecologic Oncology Group Study Gynecologic Oncology ·Elizabeth R. Burton, Mark F. Brady, Howard D. Homesley, Peter G. Rose, Toshiaki Nakamura, Joshua P. Kesterson, Jacob Rotmensch, J.T. Thigpen, Linda Van Le	2015	19
9	Independent radiologic review of the Gynecologic Oncology Group Study 0218, a phase III trial of bevacizumab in the primary treatment of advanced epithelial ovarian, primary peritoneal, or fallopian tube cancer Gynecologic Oncology ·Robert A. Burger, Mark F. Brady, Joon Haeng Rhee, Mika A. Sovak, George Kong, Hoa Nguyen, Michael A. Bookman	2013	40
10	Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer Obstetrical & Gynecological Survey ·Robert A. Burger, Mark F. Brady, Michael A. Bookman, Gini F. Fleming, Bradley J. Monk, Helen Huang, Robert S. Mannel, Howard D. Homesley, Jeffrey M. Fowler, Benjamin E. Greer, Matthew Boente, Michael J. Birrer, Sharon X. Liang	2012	197
11	Cytokine use and survival in the first-line treatment of ovarian cancer: A Gynecologic Oncology Group Study Gynecologic Oncology ·Frederick B. Stehman, Mark F. Brady, J.T. Thigpen, Emma Rossi, Robert A. Burger	2012	6
12	Nuclear P27 expression in benign, borderline (LMP) and invasive tumors of the ovary and its association with prognosis: A gynecologic oncology group study Gynecologic Oncology ·John Farley, Leia M. Smith, Kathleen M. Darcy, Mark F. Brady, Jeffrey A. Bell, William P. McGuire, Michael J. Birrer	2011	7
13	GOG 175: A Randomized phase III trial of IV carboplatin (AUC 6) and paclitaxel 175 mg/m(2) Q 21 days x 3 courses plus low-dose paclitaxel 40 mg/m(2)/wk versus IV carboplatin (AUC 6) and paclitaxel 175 mg/m(2) Q 21 days x 3 courses plus observation in patients with early-stage ovarian carcinoma Gynecologic Oncology ·Robert S. Mannel, Mark F. Brady, Elise C. Kohn, Parviz Hanjani, Masamichi Hiura, Roger Lee, Koen De Geest, David E. Cohn, Bradley J. Monk, Helen Michael	2010	0
14	Randomized phase III trial of tamoxifen versus thalidomide in women with biochemical-recurrent-only epithelial ovarian, fallopian tube or primary peritoneal carcinoma after a complete response to first-line platinum/taxane chemotherapy with an evaluation of serum vascular endothelial growth factor (VEGF): A Gynecologic Oncology Group Study Gynecologic Oncology ·Jean Hurteau, Mark F. Brady, Kathleen M. Darcy, William P. McGuire, Pamela Edmonds, Michael L. Pearl, I. I. Ivanov, Krishnansu S. Tewari, Robert S. Mannel, Kristine Zanotti, Doris M. Benbrook	2010	56
15	Evaluation of New Platinum-Based Treatment Regimens in Advanced-Stage Ovarian Cancer: A Phase III Trial of the Gynecologic Cancer InterGroup Journal of Clinical Oncology ·Michael A. Bookman, Mark F. Brady, William P. McGuire, Peter Harper, David S. Alberts, Michael Friedländer, Nicoletta Colombo, Jeffrey M. Fowler, Peter A. Argenta, Koen De Geest, David G. Mutch, Robert A. Burger, Ann Marie Swart, Edward L. Trimble, Chrisann Accario-Winslow, Lawrence M. Roth Hit paper breakdown →	2009	500
16	Survival After Second-Line Intraperitoneal Therapy for the Treatment of Epithelial Ovarian Cancer International Journal of Gynecological Cancer ·Maurie Markman, Mark F. Brady, Alan D. Hutson, Jonathan S. Berek	2009	9
17	Clinical trials in ovarian carcinoma: study methodology Annals of Oncology ·Jan B. Vermorken, Mahesh Parmar, Mark F. Brady, E. A. Eisenhauer, Thomas Högberg, Robert F. Ozols, Justine Rochon, G.J.S. Rustin, Satoru Sagae, René H.M. Verheijen	2005	20
18	Secondary Surgical Cytoreduction for Advanced Ovarian Carcinoma New England Journal of Medicine ·Peter G. Rose, Stacy Nerenstone, Mark F. Brady, Daniel L. Clarke‐Pearson, George J. Olt, Stephen C. Rubin, David H. Moore, James M. Small	2004	245
19	The Gynecologic Oncology Group experience in ovarian cancer Annals of Oncology ·William P. McGuire, Mark F. Brady, Robert F. Ozols	1999	20
20	Cyclophosphamide and Cisplatin Compared With Paclitaxel and Cisplatin in Patients with Stage III and Stage IV Ovarian Cancer Obstetrical & Gynecological Survey ·William P. McGuire, William J. Hoskins, Mark F. Brady, Paul R. Kucera, Edward E. Partridge, Katherine Y. Look, Daniel L. Clarke‐Pearson, Martin Davidson	1996	38

About Mark F. Brady

Mark F. Brady is a scholar working on Reproductive Medicine, Obstetrics and Gynecology, Oncology, Surgery and Pulmonary and Respiratory Medicine, having authored 111 papers that have together received 12.0k indexed citations. Recurring topics across this work include Ovarian cancer diagnosis and treatment (78 papers), Endometrial and Cervical Cancer Treatments (27 papers), Intraperitoneal and Appendiceal Malignancies (25 papers), Renal cell carcinoma treatment (11 papers), PARP inhibition in cancer therapy (11 papers), Reproductive Biology and Fertility (9 papers), Prostate Cancer Treatment and Research (6 papers) and Cancer, Lipids, and Metabolism (5 papers). The work is most often cited by research in Reproductive Medicine (8.4k citations), Obstetrics and Gynecology (3.9k citations), Oncology (3.7k citations), Surgery (3.7k citations) and Pathology and Forensic Medicine (1.4k citations). Mark F. Brady has collaborated with scholars based in United States, Japan and United Kingdom. Frequent co-authors include William P. McGuire, Howard D. Homesley, Paul R. Kucera, Daniel L. Clarke‐Pearson, Robert A. Burger, Katherine Y. Look, William J. Hoskins, Edward E. Partridge, Martin Davidson and Michael A. Bookman. Their work appears in journals such as Journal of Clinical Oncology, Gynecologic Oncology, Cancer, Annals of Oncology and International Journal of Gynecological Cancer.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact